Outlook Therapeutics Inc. (OTLK) Fundamentals

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
SHARE INFORMATION
Market Cap$ 273,635,007
Shares Outstanding226,144,634
Float143,617,908
Percent Float63.51%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -0.36
Latest Fiscal Date2021-09-30
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions163
Institutional Holdings Date2022-08-31
Institutional Bought Previous 3 Months1,258,341
Institutional Holdings Percent17.8%
Institutional Sold Previous 3 Months1,580,857
Insider Holdings Date2022-08-31
Insider Bought Previous 3 Months28,037,454
Insider Holdings Percent4.8
Insider Sold Previous 3 Months-
Insider Shares Owned10,756,004
TRADING INFO
52 Week High$ 2.40
52 Week Low$ 0.68
52 Week High Change$ -47.62
21 Day Moving Average$ 1.1481
21 Day Extended Moving Average$ 1.1676
50 Day Moving Average$ 1.1636
50 Day Extended Moving Average$ 1.1737
200 Day Moving Average$ 1.395
200 Day Extended Moving Average$ 1.4097
10 Day Average Volume583,308
20 Day Average Volume501,034
30 Day Average Volume443,554
50 Day Average Volume459,840
Alpha0.016611
Beta0.8638
Standard Deviation0.331610
R20.017275
7 Day Price Change$ 0.06
7 Day Percent Change5.22%
21 Day Price Change$ 0.09
21 Day Percent Change8.04%
30 Day Price Change$ 0.05
30 Day Percent Change4.31%
Month to Date Price Change$ 0.09
Month to Date Percent Change8.04%
Quarter to Date Price Change$ 0.19
Quarter to Date Percent Change18.63%
180 Day Price Change$ -0.82
180 Day Percent Change-40.39%
200 Day Price Change$ -0.52
200 Day Percent Change-30.06%
Year to Date Price Change$ -0.15
Year to Date Percent Change-11.03%

Outlook Therapeutics Inc. (OTLK) Key Ratios

PROFITABILITY
EBIT Margin-672.6%
EBITDA Margin-649.3%
Pre-Tax Profit Margin-1,057.2%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book14.00
Total Debt To Equity0.50
Int Coverage-45.60
Current Ratio2.00
Leverage Ratio1.90
Quick Ratio1.40
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-3.80
Enterprise Value$ 264,917,195
Price to Sales0.00
Price to Free Cash-5.10
PE High Last 5 Years-0.70
Price To Book14.00
Price To Cash Flow0.00
PE Low Last 5 Years-0.70
Price to Tangible Book14.00
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-192.51
Return on Equity-415.41
Return on Capital-233.60

Outlook Therapeutics Inc. (OTLK) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorKPMG LLP
CEOLawrence A. Kenyon
Emplyoees14
Last AuditUQ
CIK0001649989
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address4260 U.S. Route 1
Suite 320
Monmouth Junction, NJ 8852
Websitehttps://www.outlooktherapeutics.com
Facsimile-
Telephone+1 609 619-3990
EmailLawrenceKenyon@outlooktherapeutics.com


Your Recent History
NASDAQ
OTLK
Outlook Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.